Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats
M Fittkau, W Voigt, HJ Holzhausen… - Journal of cancer research …, 2004 - Springer
Purpose To evaluate the ability of D-saccharic acid 1.4-lactone (SAL), a β-glucuronidase
inhibitor, to prevent irinotecan hydrochloride (CPT-11) from inducing mucosal damage as a …
inhibitor, to prevent irinotecan hydrochloride (CPT-11) from inducing mucosal damage as a …
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice
CL Morton, L Iacono, JL Hyatt, KR Taylor… - Cancer chemotherapy …, 2005 - Springer
Purpose: To examine the antitumor activity and the pharmacokinetics of CPT-11 (irinotecan,
7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) in a plasma esterase …
7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) in a plasma esterase …
Carboxylesterase and UDP‐glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra‐performance liquid …
Y Qin, A Kang, G Zhou, H Wang, W Wei… - Biomedical …, 2018 - Wiley Online Library
Carboxylesterase and UDP‐glucuronosyltransferase‐mediated metabolism of irinotecan
(CPT‐11) has long been proposed to be responsible for its anti‐tumor activity and toxicity …
(CPT‐11) has long been proposed to be responsible for its anti‐tumor activity and toxicity …
HPLC determination of irinotecan and its active metabolite SN-38 in rat plasma
D LIU, J GAO, C ZHANG, D XIANG… - Chinese Journal of …, 2011 - ingentaconnect.com
Objective: To develop an HPLC method for the simultaneous determination of irinotecan
(CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) in rat plasma …
(CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) in rat plasma …
Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics
T Tamura, K Yasutake, H Nishisaki, T Nakashima… - Oncology, 2005 - karger.com
Alkalization of the intestinal tract by oral administration of sodium bicarbonate has been
reported to be a promising method for preventing delayed diarrhea, a dose-limiting toxicity in …
reported to be a promising method for preventing delayed diarrhea, a dose-limiting toxicity in …
Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines
T Takahata, K Ookawa, K Suto… - Basic & clinical …, 2008 - Wiley Online Library
Irinotecan hydrochloride (CPT‐11) is an effective anticancer drug, and its metabolic pathway
has been well studied. Nevertheless, in human hepatocellular carcinoma (HCC), its …
has been well studied. Nevertheless, in human hepatocellular carcinoma (HCC), its …
A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort
ZP Hu, XX Yang, X Chen, J Cao, E Chan… - Current drug …, 2007 - ingentaconnect.com
Irinotecan (CPT-11) is an important anticancer drug in management of advanced colon
cancer. A marked protective effect on CPT-11-induced blood and gastrointestinal toxicity is …
cancer. A marked protective effect on CPT-11-induced blood and gastrointestinal toxicity is …
Antitumor Effect of SN-38–releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with …
T Eguchi Nakajima, K Yanagihara, M Takigahira… - Cancer Research, 2008 - AACR
Ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of irinotecan hydrochloride
(CPT-11), has potent antitumor activity. Moreover, we have reported the strong antitumor …
(CPT-11), has potent antitumor activity. Moreover, we have reported the strong antitumor …
Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38
Irinotecan, or CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecine),
is a water-soluble derivative of camptothecine with promising activity against several types …
is a water-soluble derivative of camptothecine with promising activity against several types …
Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients
T Yamagata, H Kusuhara, M Morishita… - Drug metabolism and …, 2007 - ASPET
Recently, breast cancer resistance protein (BCRP/ABCG2) has been shown to limit the oral
absorption of its substrates in the intestine. The purpose of this study was to examine …
absorption of its substrates in the intestine. The purpose of this study was to examine …